Rakovina Therapeutics (TSXV:RKV) Beta: -0.2657 (As of Jun. 28, 2026)


TSXV:RKV Rakovina Therapeutics Inc TSXV:RKV
34 GF Score
Price C$0.14
! 1 Warning Sign
View Full Analysis

What is Rakovina Therapeutics Beta?

Rakovina Therapeutics TSXV:RKV +7.69% 34 Beta is -0.2657 as of Jun. 28, 2026. GuruFocus rates TSXV:RKV with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-28), Rakovina Therapeutics's Beta is -0.2657.


Rakovina Therapeutics  (TSXV:RKV) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Rakovina Therapeutics Beta Related Terms


Rakovina Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Rakovina Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rakovina Therapeutics Beta Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beta
0.00 0.00 0.00 -0.64 -0.80

Rakovina Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.32 -0.29 -0.80 0.11

TSXV:RKV vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Rakovina Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rakovina Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Beta falls into.


TSXV:RKV
34GF Score
Rakovina Therapeutics Inc TSXV:RKV
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rakovina Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.2657 mean?
Rakovina Therapeutics (TSXV:RKV) has a Beta of -0.2657 as of Jun. 28, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rakovina Therapeutics and its competitors.
Is Rakovina Therapeutics' Beta too high?
Rakovina Therapeutics' current Beta is -0.2657. Overall, Rakovina Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Rakovina Therapeutics' Beta compare to VRTX and REGN?
Rakovina Therapeutics' Beta of -0.2657 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Rakovina Therapeutics and its competitors. Rakovina Therapeutics's current Beta is -0.2657. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rakovina Therapeutics stock overvalued right now?
Rakovina Therapeutics (TSXV:RKV) has a current Beta of -0.2657. The current Beta is -0.2657. Rakovina Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Rakovina Therapeutics (TSXV:RKV), the current Beta is -0.2657 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rakovina Therapeutics Business Description

Other Exchanges RKVTF:USA7JO0:Germany
Address 999 West Broadway, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a greater pace. The company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Its drug development pipeline consists of candidates like kt-5000AI, kt-2000AI, and kt-3283, targeting solid tumours and PARP-resistant adult and childhood cancers.
34GF Score

Get the complete analysis for TSXV:RKV

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.14
Price